News
TRAW
4.840
+2.11%
0.100
Weekly Report: what happened at TRAW last week (1007-1011)?
Weekly Report · 3d ago
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment
Barchart · 10/10 12:28
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW)
TipRanks · 10/09 12:30
Traws Pharma Reports Topline Phase 1 Safety And Pharmacokinetic Results For Investigational One-dose Flu Therapy, Tivoxavir Marboxil; Preclinical Data Showed Potent Inhibition Of Drug-resistant And Bird Influenza Viruses
Benzinga · 10/08 11:40
Traws Pharma announces topline Phase 1 data for tivoxavir marboxil
TipRanks · 10/08 11:35
TRAWS PHARMA INC - NO TREATMENT RELATED ADVERSE EVENTS REPORTED AT PHASE 2 DOSE
Reuters · 10/08 11:30
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Barchart · 10/08 06:30
Weekly Report: what happened at TRAW last week (0930-1004)?
Weekly Report · 10/07 09:59
Noble Financial Sticks to Its Buy Rating for Traws Pharma (TRAW)
TipRanks · 10/01 12:05
Traws Pharma announces results from its early stage trial for its COVID candidate
Seeking Alpha · 09/30 14:39
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/30 12:06
Traws Pharma announces topline Phase 1 results for ratutrelvir
TipRanks · 09/30 11:41
Traws Pharma Announced Topline Phase 1 Results For Its Covid Candidate, Ratutrelvir, An Oral Inhibitor Of The Main Protease
Benzinga · 09/30 11:32
TRAWS PHARMA INC - NO TREATMENT RELATED ADVERSE EVENTS REPORTED UP TO HIGHEST DOSE
Reuters · 09/30 11:30
Weekly Report: what happened at TRAW last week (0923-0927)?
Weekly Report · 09/30 09:57
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Barchart · 09/30 06:30
Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested
TipRanks · 09/23 10:48
More
Webull provides a variety of real-time TRAW stock news. You can receive the latest news about Traws Pharma through multiple platforms. This information may help you make smarter investment decisions.
About TRAW
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).